Clinical Services

Clinical Services aims to be the market leader in servicing clinical trials and supplying quality-assured comparator medicines internationally. Its strategic focus is on:

  • Establishing Clinigen with customer compounds earlier in the product lifecycle
  • Improving visibility and quality of revenue streams through diversification of customer base, longer-term contracts and exclusive supply arrangements
  • Presenting product opportunities to Unlicensed Medicines business operation
18%

OF ADJUSTED GROUP GROSS PROFIT

MARKET DRIVERS

  • Need for agility, flexibility and rapid response times to meet client demands
  • Clients increasingly require more complex solutions (such as growth of IIT market) from fewer vendors
  • Drive to reduce the cost of clinical development (i.e. comparator product sourcing) and time to market

CLINIGEN RESPONSE AND DIFFERENTIATORS

  • Global supply chain and distribution network
  • Qualified supply chain certifies product for authenticity
  • Integrated service offering from clinical trial, to IITs to early access
  • Regulatory expertise
  • Broad and embedded relationships with both pharmaceutical and biotech clients and HCP customers

Unlicensed Medicines

Clinigen is the international leader in ethically sourcing, managing and supplying unlicensed medicines to hospital pharmacists and physicians for patients with a high unmet medical need. The Group manages MAPs to innovative new medicines and provides global access to medicines which remain unlicensed at the point of care.

Its aim is to be the first point of call for HCPs to source hard to access, unlicensed medicines through its strategy of:

  • Developing a rich pipeline based on industry trends and innovation
  • Providing a world-class customer service to HCPs, sourcing hard to access medicines for their patients
  • Converting MAPs to long-term exclusive supply agreementsĀ 
38%

OF ADJUSTED GROUP GROSS PROFIT

MARKET DRIVERS

  • Increased role of patient advocacy groups and online resources leading to greater patient demand
  • Clients increasingly wanting a global partner to manage supply and distribution beyond managed access
  • Increased risk of counterfeit and substandard medicines entering the supply chain

CLINIGEN RESPONSE AND DIFFERENTIATORS

  • Broad and embedded relationships with pharmaceutical companies
  • Expert understanding of complex regulatory environments globally
  • Global supply chain and distribution network
  • Proprietary online management platform
  • Ability to manage unlicensed supply from Managed Access to Global Access

Commercial Medicines

The strategy for Commercial Medicines is threefold in order to build a portfolio that can deliver sustainable growth through:

  • Continued revitalisation/growth of current portfolio of niche hospital-only and critical care products, coupled with selective product acquisitions
  • Being the licensing partner of choice for pharmaceutical and biotech clients in non-core territories through regional licensing agreements
  • Developing a long-term pipeline of medicines and launch licensed products through the UL2L model
44%

OF ADJUSTED GROUP GROSS PROFIT

MARKET DRIVERS

  • Portfolio rationalising by large pharmaceutical companies
  • Clients increasingly looking to rationalise territories and partner with regional specialists to manage the lifecycle of products
  • Increased pressure to have unlicensed products available as licensed products by regulatory authorities, HCPs and patients to improve access

CLINIGEN RESPONSE AND DIFFERENTIATORS

  • Broad and embedded relationships with pharmaceutical companies
  • Proven revitalisation capability
  • Expert understanding of complex regulatory environments globally
  • Capability to convert unlicensed medicines to licensed medicines
  • Growing MSL and sales capability in the US, EU and selected AAA territories